https://losingweightrx.com/news/retatrutide-triumph-1-phase-3-weight-loss-results Losing Weight RX en 2026-05-29 Retatrutide Delivers 28% Weight Loss in TRIUMPH-1 Phase 3 Trial https://losingweightrx.com/news/nih-study-explains-glp1-weight-loss-plateaus Losing Weight RX en 2026-05-29 NIH Study Explains Why GLP-1 Weight Loss Plateaus Happen https://losingweightrx.com/news/medicare-wegovy-zepbound-coverage-july-2026 Losing Weight RX en 2026-05-29 Medicare to Cover Wegovy and Zepbound at $50/Month Starting July 1 https://losingweightrx.com/news/glp1-drugs-cancer-metastasis-risk-asco-2026 Losing Weight RX en 2026-05-29 GLP-1 Drugs Linked to Lower Cancer Metastasis Risk in ASCO Study https://losingweightrx.com/news/semaglutide-exercise-muscle-preservation-study Losing Weight RX en 2026-05-29 Combining Semaglutide With Exercise Preserves Muscle, Boosts Fat Loss https://losingweightrx.com/news/fda-peptide-guidelines-restrict-sermorelin-access Losing Weight RX en 2026-05-29 FDA Peptide Rules Restrict Sermorelin Access https://losingweightrx.com/news/elysium-health-launches-waitlist-personalized-longevity-teli Losing Weight RX en 2026-05-29 Elysium Health Launches Longevity Program Waitlist https://losingweightrx.com/news/nadrestore-trial-recommends-split-dosing-muscle-nad Losing Weight RX en 2026-05-29 NADRESTORE Trial Backs Split-Dosing for Muscle NAD+ https://losingweightrx.com/news/uconn-study-warns-against-combining-senolytic-longevity-drugs Losing Weight RX en 2026-05-29 UConn Warns Against Combining Senolytic Longevity Drugs https://losingweightrx.com/news/cvs-caremark-cover-foundayo-restore-zepbound Losing Weight RX en 2026-05-29 CVS Caremark Expands Zepbound and Foundayo Coverage https://losingweightrx.com/news/ai-uncovers-hidden-glp1-side-effects-reddit-study Losing Weight RX en 2026-05-30 AI Uncovers Hidden GLP-1 Side Effects From 400K Reddit Posts https://losingweightrx.com/news/fda-proposes-permanent-ban-compounded-semaglutide-tirzepatide Losing Weight RX en 2026-05-30 FDA Proposes Permanent Ban on Compounded GLP-1 Drugs https://losingweightrx.com/news/wegovy-eye-stroke-risk-higher-than-ozempic-bmj-study Losing Weight RX en 2026-05-30 Wegovy Linked to 5x Higher Eye Stroke Risk vs Ozempic https://losingweightrx.com/news/glp1-brain-reward-circuit-emotional-blunting-study Losing Weight RX en 2026-05-30 GLP-1 Drugs and the Brain: Study Maps Reward Changes https://losingweightrx.com/news/fda-advisory-panel-review-bpc157-tb500-peptides-july Losing Weight RX en 2026-05-30 FDA Advisory Panel to Review BPC-157, TB-500 and 5 Other Peptides in July https://losingweightrx.com/news/survodutide-phase-3-synchronize-weight-loss-results Losing Weight RX en 2026-05-31 Survodutide Phase 3 SYNCHRONIZE-1 Hits Endpoints With 16.6% Weight Loss https://losingweightrx.com/news/genetic-variants-predict-glp1-weight-loss-response-nature Losing Weight RX en 2026-05-31 GWAS Identifies Genetic Variants Linked to GLP-1 Response https://losingweightrx.com/news/glp1-drugs-reduce-substance-abuse-suicide-veterans-bmj Losing Weight RX en 2026-05-31 GLP-1 Drugs Linked to Lower Substance Abuse and Suicide Risk in Veterans https://losingweightrx.com/news/glp1-microdosing-trend-viral-no-clinical-evidence Losing Weight RX en 2026-05-31 GLP-1 Microdosing Goes Viral Despite No Clinical Evidence https://losingweightrx.com/news/semaglutide-cuts-heavy-drinking-lancet-rct-alcohol Losing Weight RX en 2026-05-31 Semaglutide Cuts Heavy Drinking Days 41% in Lancet RCT https://losingweightrx.com/news/foundayo-vs-oral-wegovy-head-to-head-lancet-data Losing Weight RX en 2026-06-01 Foundayo vs Oral Wegovy: Head-to-Head Lancet Data Fuels Debate https://losingweightrx.com/news/glp1-drugs-linked-30-percent-higher-osteoporosis-risk-5-years Losing Weight RX en 2026-06-01 GLP-1 Drugs Linked to 30% Higher Osteoporosis Risk After 5 Years https://losingweightrx.com/news/fda-compounding-comment-period-closing-june-29-glp1 Losing Weight RX en 2026-06-01 FDA Compounding Comment Period Closing June 29 for GLP-1 Drugs https://losingweightrx.com/news/asco-2026-glp1-endometrial-cancer-mortality-55-percent Losing Weight RX en 2026-06-01 ASCO 2026: GLP-1 Drugs Cut Endometrial Cancer Mortality by 55% https://losingweightrx.com/news/high-dose-wegovy-7-2mg-real-world-experience-results Losing Weight RX en 2026-06-01 High-Dose Wegovy 7.2 mg: Real-World Experience Emerges Post-Approval https://losingweightrx.com/news/roche-ct388-petrelintide-combination-obesity-trial Losing Weight RX en 2026-06-02 Roche to Trial CT-388 and Petrelintide Obesity Combo https://losingweightrx.com/news/astrazeneca-oral-glp1-elecoglipron-phase-3-trial Losing Weight RX en 2026-06-02 AstraZeneca to Push Oral GLP-1 Elecoglipron into Phase 3 https://losingweightrx.com/news/novo-nordisk-zenagamtide-amaze-phase-3-obesity-trial Losing Weight RX en 2026-06-02 Novo Nordisk Launches AMAZE Phase 3 Program for Zenagamtide https://losingweightrx.com/news/oral-semaglutide-oasis-4-trial-weight-loss-mobility Losing Weight RX en 2026-06-02 Oral Semaglutide OASIS 4 Sub-Analysis: 21.6% Weight Loss https://losingweightrx.com/news/nadream-clinical-trial-nicotinamide-riboside-sleep-mitochondria Losing Weight RX en 2026-06-02 Clinical Trial Tests NR Effect on Sleep Quality https://losingweightrx.com/news/stanford-study-pgdhi-muscle-loss-glp1 Losing Weight RX en 2026-06-03 Stanford Study: PGDHi Spares Muscle During GLP-1 Weight Loss https://losingweightrx.com/news/cigna-drops-employee-glp1-weight-loss-coverage Losing Weight RX en 2026-06-03 Cigna to End Employee GLP-1 Weight-Loss Coverage https://losingweightrx.com/news/tru-niagen-narb-advertising-scrutiny-longevity-claims Losing Weight RX en 2026-06-03 NARB Recommends Modifying Tru Niagen Anti-Aging Ads https://losingweightrx.com/news/jacc-flow-subgroup-semaglutide-kidney-protection Losing Weight RX en 2026-06-03 FLOW Subgroup Confirms Semaglutide Kidney Protection https://losingweightrx.com/news/lilly-orforglipron-achieve4-cardiovascular-safety-results Losing Weight RX en 2026-06-03 ACHIEVE-4 Trial: Oral Orforglipron Shows Cardiac Safety